（来源：经济参考报） "医保部门始终紧盯前沿医疗技术发展，以政策创新推动技术从临床探索走向规模化应用，脑机接口技 术的支持过程成为典型范例。"谢章澍说。 事实上，早在2025年3月，医保部门就率先设立了脑机接口的相关价格和收费依据，解决了技术应用付 费难题；当年9月实现医保结算赋码，12月已有28个省份制定具体收费项目，推动技术在全国范围内铺 开应用。 "这体现了医保部门对未来产业的前瞻性布局。除脑机接口外，远程操作、质子重离子治疗、CAR-T肿 瘤治疗等一系列新技术、新药品也被纳入医保支持范畴，让群众切实享受到创新成果。"谢章澍表示。 在支持国内创新的同时，医保部门还积极搭建国际化平台，推动中国医药创新成果走向世界。此外，真 实世界医保综合价值评价作为医保目录准入、价格立项等医保决策的重要证据，既为创新技术提供了进 入临床收费的依据，也助力科学定价，为医保基金价值购买服务。 "展望'十五五'，医疗保障部门将继续深化'政策引导'与'价值评价'的双轮驱动战略，继续优化对脑机接 口等创新技术的价格支付政策，并积极开展真实世界医保综合价值评价，为医保决策科学化提供有力支 持。"谢章澍说。 "作为主要的民生保障部门， ...

Group 1 - The National Healthcare Security Administration (NHSA) has included 79 hospitals in the national credible evaluation point network for real-world healthcare value assessment [2] - The NHSA aims to ensure the credibility of evaluations by involving credible evaluation points in three key areas: entry assessment, data verification, and quality assurance [2][3] - The NHSA emphasizes the importance of professional personnel from credible evaluation points to assist in reviewing evaluation proposals to ensure they meet scientific and clinical needs [2] Group 2 - The NHSA plans to enhance data authenticity by inviting credible evaluation points to participate in checks and verify original data, addressing any identified deficiencies [2] - The NHSA encourages credible evaluation points to engage in peer evaluations to maintain the quality of assessments and produce trustworthy evaluation reports [2] - The NHSA aims to establish an information-sharing mechanism among credible evaluation points to improve the efficiency and quality of healthcare evaluations [3]

记者：孙秀艳 近日，真实世界医保综合价值评价国家可信评价点网络正式组建。79家医疗机构在京共同签署《真实世 界医保综合价值评价国家可信评价点网络公约》。据悉，网络所覆盖的医疗机构将承担真实世界医保综 合价值评价职责，助力医保部门科学决策。 国家医保局副局长施子海介绍，开展真实世界医保综合价值评价，就是要打造一套科学、权威的评价标 尺，依托真实、可信的数据，客观、完整、准确地识别医药产品的临床获益与综合价值，支持医保政策 制定。在此过程中，以可信评价点为代表的广大医疗机构，在产生数据、制定规范、开展研究等方面能 够发挥关键作用。 长期以来，医保对医药产品和医疗服务价值的判断主要依靠相关部门的权威结论和临床专家的专业判 断，存在一定的局限性。去年9月，国家医保局发布通知，开展真实世界医保综合价值评价试点工作。 国家医保局副局长施子海介绍，开展真实世界医保综合价值评价，就是要打造一套科学、权威的评价标 尺，依托真实、可信的数据，客观、完整、准确地识别医药产品的临床获益与综合价值，支持医保政策 制定。在此过程中，以可信评价点为代表的广大医疗机构，在产生数据、制定规范、开展研究等方面能 够发挥关键作用。 长期以来，医保 ...

此次在医保部门和相关部委见证下，北京大学人民医院等79家头部医疗机构负责人在北京共同签署《真 实世界医保综合价值评价国家可信评价点网络公约》，成立国家可信评价点网络。网络所覆盖的医疗机 构将主动担当真实世界医保综合价值评价的职责，助力医保部门科学决策。 中证报中证网讯（记者 傅苏颖）日前，真实世界医保综合价值评价国家可信评价点网络组建并现场签 约。 国家医保局副局长施子海表示，开展真实世界医保综合价值评价，就是要打造一套科学、权威的评价标 尺，依托真实、可信的数据，客观、完整、准确地识别医药产品的临床获益与综合价值，支持医保政策 制定和决策。在此过程中，以可信评价点为代表的广大医疗机构，在产生数据、制定规范、开展研究等 方面能够发挥不可替代的作用。希望各可信评价点发挥带头作用，做真实可信评价的率先发起者，真实 世界数据的坚实贡献者，统一评价体系的共同建设者，立足三医协同发展和治理，积极投身医保综合价 值评价这项开创性事业。 ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) has signed agreements with 79 hospitals to initiate a pilot program for real-world comprehensive value assessment of medical insurance, aiming to evaluate the effectiveness, safety, and economic value of pharmaceutical products post-market [1] Group 1: Real-World Research and Evaluation - Real-world research refers to the assessment of the effectiveness, safety, and economic value of medical products based on data generated from daily clinical practices [1] - The NHSA acknowledges that while a dynamic adjustment mechanism for the medical insurance catalog is in place, challenges remain in decision-making due to the idealized conditions of pre-market clinical trials [1][6] - The evaluation will incorporate patient experiences and satisfaction, addressing the discrepancies between clinical trial populations and the broader patient population [3] Group 2: Data Collection and Analysis - Comprehensive data collection will include patient demographics, treatment plans, clinical outcomes, and adverse effects of medications [5] - Real-world data can reveal complexities and uncertainties, such as the actual incidence of side effects that may differ from clinical trial results [8] - The use of real-world data will enable clearer insights into which medications genuinely improve patient quality of life and which medical services offer better cost-effectiveness [8] Group 3: Implications for Healthcare Funding - The real-world comprehensive value assessment is expected to enhance the efficiency of healthcare fund allocation, allowing for the identification and exclusion of high-cost, low-efficacy drugs [10] - This approach aims to create a more patient-centered healthcare system by prioritizing innovative technologies and services that meet actual patient needs [10]

Core Viewpoint - The establishment of the "National Credible Evaluation Point Network for Real-World Comprehensive Value Assessment of Medical Insurance" marks a significant step in integrating real-world data into China's medical insurance decision-making process, creating a new "value metric" for evaluating the clinical effectiveness and overall impact of medical products on patient quality of life and resource allocation [1][2][4]. Group 1: Establishment of the Network - A total of 79 medical institutions signed the agreement to form the credible evaluation point network, which will play a crucial role in supporting scientific decision-making for medical insurance [1][2]. - The network is designed to be open and dynamic, allowing for the inclusion of additional institutions based on their research achievements and contributions to the evaluation process [6]. Group 2: Evaluation Framework - The National Medical Insurance Administration has drafted guidelines for the real-world comprehensive value assessment of drugs, which outline the evaluation objects, processes, and methodological frameworks [2][5]. - The shift from traditional theoretical models to evaluations based on clinical real-world data signifies a transformation in the medical insurance evaluation system [2]. Group 3: Impact on Medical Institutions - Medical institutions involved in the network will be responsible for generating data, establishing standards, and conducting research, thereby playing an irreplaceable role in the evaluation process [4][6]. - The network aims to fill the gap in real-world research that has previously been lacking, ensuring that the clinical application of drugs and medical supplies is adequately studied [6]. Group 4: Future Implications for Pharmaceutical Companies - Real-world comprehensive value assessments will provide objective evidence for medical insurance decision-making, influencing the dynamic adjustment of the medical insurance catalog [9]. - Pharmaceutical companies are encouraged to conduct real-world studies during the critical period between clinical trials and drug applications to provide more evidence for insurance decisions [9][10]. - The establishment of incentive mechanisms linked to insurance negotiations will motivate pharmaceutical companies to engage in real-world value assessments, impacting future negotiations and payment standards [10].

Core Insights - The establishment of the National Credible Evaluation Point Network for Real-World Medical Insurance Comprehensive Value Assessment aims to scientifically evaluate the actual value of pharmaceutical products using real clinical data [1][2] - The initiative involves 79 leading medical institutions and is intended to support key decisions in medical insurance, including drug negotiations and pricing [1] - The network will provide objective evidence for the adjustment of the medical insurance catalog, ensuring that the benefits and cost-effectiveness of negotiated drugs are in line with initial expectations [1] Group 1 - The Real-World Research focuses on evaluating the effectiveness, safety, and economic value of pharmaceutical products based on data generated from daily clinical practices [1] - The National Healthcare Security Administration (NHSA) emphasizes the importance of real-world research as a foundational work for medical insurance decision-making [1] - The NHSA plans to conduct evaluations every two years for negotiated drugs to ensure their benefits align with expectations [1] Group 2 - The NHSA aims for each credible evaluation point to participate in at least one real-world comprehensive value assessment of a drug, consumable, or medical service by 2026 [2] - The initiative is expected to generate demonstrable results that can withstand scrutiny and be applied in practical scenarios [2]

Core Viewpoint - The establishment of the National Credible Evaluation Point Network aims to enhance the scientific decision-making of medical insurance departments through real-world comprehensive value evaluation of medical products [1] Group 1: Establishment and Purpose - 79 medical institutions have signed the "National Credible Evaluation Point Network Convention" to form the National Credible Evaluation Point Network [1] - The initiative is designed to create a scientific and authoritative evaluation standard based on real and credible data to objectively identify the clinical benefits and comprehensive value of medical products [1] Group 2: Role of Medical Institutions - Medical institutions represented by the credible evaluation points will play an irreplaceable role in data generation, standard formulation, and research [1] - The network members will lead a series of comprehensive value evaluation studies based on the needs of medical insurance decision-making and application scenarios [1] Group 3: Collaboration and Future Research - The medical insurance department encourages collaboration with various institutions, including the National Credible Evaluation Point Network, to conduct research that supports scientific decision-making in medical insurance [1]

Core Viewpoint - The establishment of the National Trustworthy Evaluation Point Network marks a significant step in supporting scientific decision-making in healthcare insurance through real-world research [1][4]. Group 1: Establishment of the Network - 79 medical institutions, including Peking University People's Hospital and Shanghai Sixth People's Hospital, have signed the National Trustworthy Evaluation Point Network Agreement [1]. - The network aims to create a scientific and authoritative evaluation standard based on real and credible data to objectively identify the clinical benefits and comprehensive value of medical products [1][4]. Group 2: Role of Trustworthy Evaluation Points - Trustworthy evaluation points will play an irreplaceable role in data generation, standard formulation, and research execution [1][4]. - The network is expected to contribute to the establishment of a value-oriented, real-world research-based comprehensive evaluation system for healthcare insurance over the next three years [4]. Group 3: Data Quality and Evaluation Process - High-quality data accumulation, scientific research design, and rigorous evaluation systems are essential for forming credible evidence [4]. - Multi-disciplinary expert involvement is necessary throughout the process to ensure the quality of evidence that can be adopted in decision-making [4]. Group 4: Future Directions and Collaboration - The National Healthcare Security Administration will guide trustworthy evaluation points to collect information regularly and share innovative ideas and solutions [5]. - The network is designed to be open and dynamic, allowing for the inclusion of outstanding external research institutions and the adjustment of non-compliant institutions [5].

Core Insights - The National Healthcare Security Administration has issued a notice to initiate pilot programs for real-world comprehensive value assessment of medical insurance in select regions including Haidian District of Beijing, Dalian City of Liaoning Province, and Shenzhen City of Guangdong Province [1] Group 1: Pilot Program Details - The pilot regions will focus on research directions such as comprehensive value assessment of drugs based on real-world data, unmet clinical needs research, and how healthcare data can support real-world studies [1] - The research outcomes will support healthcare decision-making and encourage pilot regions to prioritize the application of these findings for new or adjusted medical consumables charging directories and new medical service project approvals [1] Group 2: Future Goals - By the end of 2027, the pilot regions aim to establish a value-oriented, real-world research-based comprehensive value assessment system for medical insurance, which will be promoted nationwide [1]